Request Trial
shutterstock_1642618876_tada_images
Tada Images / Shutterstock.com
7 January 2021Americas

MSD and Glenmark appeal pay-for-delay Zetia dispute

Pharmaceutical companies MSD (known as 'Merck & Co' in the US) and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia (ezetimibe) should be reversed because the circumstances of the class members do not justify an award of class status.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Natera and a rival draw the line under five-year fight
27 February 2026   The companies have agreed to dismiss their long-running patent fight over tumour-informed liquid biopsy technology, closing a high-stakes chapter in the fast-growing MRD testing market—while leaving the door open to future claims.
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026   As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026   In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.


Editor's picks

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026

Editor's picks

Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026

More features

Natera and a rival draw the line under five-year fight
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
Eli Lilly escapes $278m payout in biotech licensing dispute
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
Wiggin’s new litigation partner deepens ‘technically complex’ offer
Could everyday hospital equipment be the next defence against counterfeit medicines?
BioNTech fires shots at Moderna's next-generation vaccine
Mintz gains ex-Winston & Strawn partner and ITC expert